Evotec shares fall 1.57% premarket after reporting H1 2025 results with mixed revenue performance.

Evotec SE declined 1.57% in premarket trading. The company reported its H1 2025 results, highlighting strong progress on strategy execution with improving revenue mix and ahead-of-plan cost reductions. However, the Discovery & Preclinical Development segment saw soft demand, which may have contributed to the stock's decline. Additionally, the anticipated sale of the biopharmaceutical production facility in Toulouse, France, did not significantly boost investor confidence, as the stock faced resistance from the 21-day moving average.